DXCMDexcom
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. 10-K, Item 1
- Employees
- 11,100
- Headquarters
- San Diego, CA
- CEO
- Jacob Steven Leach
- Next results
- around Jan 11, 2027
Dilution: new shares, stock pay and buybacks
prospectuses (S-3, 424B) of the last three years and the 10-K cash flow From EDGARShares offered
Since Nov 11, 2023: 1 shelf registration.
- Feb 18, 2025 Shelf registration: shares and other securities, amount not fixed S-3ASR
Every offering filing →“Under this shelf registration process, we may, from time to time, sell an indeterminate amount of any combination of the securities described in this prospectus in one or more offerings.”
S-3ASR, Feb 18, 2025 ↗
Diluted shares: 405.50M in the year to Dec 31, 2025 2025 -1.7%2024 -3.0%2023 -0.5%2022 -0.3%
Change in the diluted weighted average share count from the fiscal year before, stock splits taken out. Bars use one scale for stock pay and buybacks. Prospectuses are read from their cover page; preliminary ones are left out. Cash & buybacks, year by year → · How
FY2025, from the cash flow statement in the 10-K, added up.
Came from
| Operating cash flow | $1.4B |
| Shares sold | $28.1M |
Went to
| Capital spending | $363.5M |
| Buybacks | $500.0M |
| Added to cash | $311.8M |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$293.5M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
| Fiscal year to | Buybacks | Dividends | Stock pay | Shares issued for cash | Diluted shares |
|---|---|---|---|---|---|
| 2025-12-31 | $500.0M | - | $159.6M | $28.1M | 405.50M |
| 2024-12-31 | $750.0M | - | $170.4M | $28.2M | 412.70M |
| 2023-12-31 | $688.7M | - | $150.8M | $26.6M | 425.50M |
| 2022-12-31 | $557.7M | - | $126.5M | $22.5M | 427.50M |
| 2021-12-31 | $0 | - | $113.4M | $20.3M | 428.80M |
From the XBRL of the 10-Ks (cash flow statement and diluted weighted average shares); each year as reported in the latest 10-K that includes it. Concepts: buybacks = PaymentsForRepurchaseOfCommonStock; sbc = ShareBasedCompensation; issuance = ProceedsFromIssuanceOfCommonStock; diluted_shares = WeightedAverageNumberOfDilutedSharesOutstanding.
Price paid per share
What DXCM paid on average for each share it bought back, each fiscal year: dollars spent divided by shares bought, both from the 10-K.
| Fiscal year to | Shares bought | Spent | Average price | |
|---|---|---|---|---|
| 2025-12-31 | 7.70M | $503.6M | $65.40 | |
| 2024-12-31 | 10.40M | $749.5M | $72.07 | |
| 2023-12-31 | 4.70M | $689.2M | $146.64 | |
| 2022-12-31 | 6.60M | $557.7M | $84.50 | |
| 2018-12-31 | 800K | $100.0M | $125.00 |
Shares and dollars from the statement of shareholders' equity (the cash flow line also counts shares withheld for taxes, so it is not used). Share counts filed before a stock split are put on today's count. A year where the 10-K does not tag both numbers is left out.
Work on DXCM in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DXCM/export.csv") into a cell.